Prosecution Insights
Last updated: April 19, 2026
Application No. 16/617,687

COMPOSITIONS

Non-Final OA §103§112
Filed
Nov 27, 2019
Examiner
MORNHINWEG, JEFFREY P
Art Unit
1793
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Givaudan S A
OA Round
9 (Non-Final)
36%
Grant Probability
At Risk
9-10
OA Rounds
3y 11m
To Grant
70%
With Interview

Examiner Intelligence

Grants only 36% of cases
36%
Career Allow Rate
200 granted / 558 resolved
-29.2% vs TC avg
Strong +34% interview lift
Without
With
+33.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
62 currently pending
Career history
620
Total Applications
across all art units

Statute-Specific Performance

§101
3.0%
-37.0% vs TC avg
§103
48.8%
+8.8% vs TC avg
§102
15.6%
-24.4% vs TC avg
§112
22.0%
-18.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 558 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Application Receipt of the Request for Continued Examination (RCE under 37 CFR 1.114), the Response and Amendment filed 01/09/2026 is acknowledged. The application was transferred to the present examiner as of the response filed 01/09/2026. Applicant has overcome the following rejections by virtue of the cancellation of the claims: (1) the 35 U.S.C. 112(b) rejections of claims 85, 94, and 106 have been withdrawn; and (2) the 35 U.S.C. 103 rejections of claims 85, 87, 89, 91, 92, 94, and 96-110 over Hansen, Yoshinaka, Bernal, Murata, and Markosyan have been withdrawn. The status of the claims upon entry of the present amendment stands as follows: Pending claims: 85, 87, 89, 91, 92, 94, and 96-110 Withdrawn claims: None Previously canceled claims: 1-84, 86, 88, 90, 93, and 95 Newly canceled claims: 85, 87, 89, 91, 92, 94, and 96-110 Amended claims: None New claims: 111-124 Claims currently under consideration: 111-124 Currently rejected claims: 111-124 Allowed claims: None Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant’s submission filed on 01/09/2026 has been entered. Claim Objections Claims 113-119 are objected to because of the following informalities: the claims depend from canceled claims. Appropriate correction is required. The claims are presumed to be intended to depend from claim 111 for those claims reciting claim 1, and claim 112 for those claims reciting claim 2. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 113 and 117 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claims 113 and 117 require only that “the at least one sweetener is a nutritive or non-nutritive sweetener”, which fails to further limit the subject matter of the parent claims, since any sweetener may be designated as being either nutritive or non-nutritive. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 103 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 111-124 are rejected under 35 U.S.C. 103 as being unpatentable over Prakash et al. (U.S. 2015/0017284 A1). Regarding claim 111, Prakash et al. discloses a sweetened composition comprising a sweetener ([0299]-[0302]; [0305]-[0306]) in an amount having a sweetness equal to or greater than 1.5% (w/v) sucrose equivalence ([0585], where the composition may comprise 100-140,000 ppm, or 0.01-14% w/v, of a carbohydrate sweetener; [0306], where the carbohydrate sweetener may be sucrose) and a sweetness enhancer comprising neomogroside in an amount of 15-50 ppm (specifically, about 0.01-3,000 ppm) ([0305]-[0309]). The disclosure of Prakash et al. is not considered to disclose the claimed ranges with sufficient specificity to support an anticipation rejection under 35 U.S.C. § 102(a)(1), so the rejection is under 35 U.S.C. § 103 on the basis of obviousness. MPEP 2131.03 II. As for claim 112, Prakash et al. discloses the sweetness enhancer as being present in a total amount ranging from 15-35 ppm (specifically, about 0.01-3,000 ppm) ([0309]). As for claim 113, Prakash et al. discloses the sweeteners as being nutritive ([0306]) and non-nutritive ([0299]). As for claim 114, Prakash et al. discloses the at least one sweetener as being a steviol glycoside ([0299]). As for claim 115, Prakash et al. discloses the composition as being a beverage ([0576], [0585]). As for claim 116, Prakash et al. discloses the sweetness enhancer “can be provided as a pure compound” ([0309]), which renders the claimed range of at least 80 wt% pure obvious. As for claim 117, Prakash et al. discloses the sweeteners as being nutritive ([0306]) and non-nutritive ([0299]). As for claim 118, Prakash et al. discloses the at least one sweetener as being a steviol glycoside ([0299]). As for claim 119, Prakash et al. discloses the sweetness enhancer “can be provided as a pure compound” ([0309]), which renders the claimed range of at least 80 wt% pure obvious. As for claim 120, Prakash et al. discloses a method comprising adding neomogroside in an amount of 15-50 ppm ([0305]-[0309]) to a sweetened composition ([0299]-[0302], [0577]). Although Prakash et al. does not explicitly disclose the neomogroside as being added as a “sweetness enhancer”, the disclosed method is adequate to render the claimed method obvious. MPEP 2144 IV (“The reason or motivation to modify the reference may often suggest what the inventor has done, but for a different purpose or to solve a different problem. It is not necessary that the prior art suggest the combination to achieve the same advantage or result discovered by applicant.”). As for claim 121, Prakash et al. discloses the sweetness enhancer as being present in a total amount ranging from 15-35 ppm (specifically, about 0.01-3,000 ppm) ([0309]). As for claim 122, Prakash et al. discloses the composition as being a beverage ([0576], [0585]). As for claim 123, Prakash et al. discloses the sweetness enhancer “can be provided as a pure compound” ([0309]), which renders the claimed range of at least 80 wt% pure obvious. As for claim 124, Prakash et al. discloses the sweetness enhancer “can be provided as a pure compound” ([0309]), which renders the claimed range of at least 80 wt% pure obvious. Response to Arguments Claim Rejections - 35 U.S.C. § 112: Applicant has overcome the 35 U.S.C. § 112(b) rejections of claims 85, 94, and 106 based on cancellation of the claims. Accordingly, the 35 U.S.C. § 112(b) rejections have been withdrawn. Claim Rejections - 35 U.S.C. § 103 of claims 85, 87, 89, 91, 92, 94, and 96-110 over Hansen, Yoshinaka, Bernal, Murata, and Markosyan: Applicant has overcome the 35 U.S.C. § 103 rejections of claims 85, 87, 89, 91, 92, 94, and 96-110 based on cancellation of the claims. Accordingly, the 35 U.S.C. § 103 rejections have been withdrawn. Conclusion Claims 111-124 are rejected. No claims are allowed at this time. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JEFFREY P MORNHINWEG whose telephone number is (571)270-5272. The examiner can normally be reached 8:30AM-5:00PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Emily Le can be reached at 571-272-0903. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JEFFREY P MORNHINWEG/Primary Examiner, Art Unit 1793
Read full office action

Prosecution Timeline

Nov 27, 2019
Application Filed
Oct 22, 2021
Response after Non-Final Action
Nov 03, 2021
Response after Non-Final Action
Mar 11, 2022
Non-Final Rejection — §103, §112
Aug 16, 2022
Response Filed
Sep 29, 2022
Final Rejection — §103, §112
Feb 01, 2023
Request for Continued Examination
Feb 04, 2023
Response after Non-Final Action
Mar 23, 2023
Non-Final Rejection — §103, §112
May 11, 2023
Response Filed
May 11, 2023
Response after Non-Final Action
Aug 10, 2023
Final Rejection — §103, §112
Aug 29, 2023
Applicant Interview (Telephonic)
Aug 29, 2023
Examiner Interview Summary
Sep 15, 2023
Request for Continued Examination
Oct 05, 2023
Response after Non-Final Action
Apr 18, 2024
Non-Final Rejection — §103, §112
Jul 24, 2024
Response Filed
Sep 11, 2024
Final Rejection — §103, §112
Nov 05, 2024
Request for Continued Examination
Nov 09, 2024
Response after Non-Final Action
Feb 25, 2025
Non-Final Rejection — §103, §112
May 28, 2025
Response Filed
Jul 09, 2025
Final Rejection — §103, §112
Aug 26, 2025
Examiner Interview Summary
Jan 09, 2026
Request for Continued Examination
Jan 12, 2026
Response after Non-Final Action
Mar 05, 2026
Non-Final Rejection — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599157
NATURAL SWEETENING FLAVOR COMPOSITION
2y 5m to grant Granted Apr 14, 2026
Patent 12550923
ALLULOSE SYRUPS
2y 5m to grant Granted Feb 17, 2026
Patent 12520863
Compositions used for sweetened substances
2y 5m to grant Granted Jan 13, 2026
Patent 12514274
GRANULATION OF A STEVIA SWEETENER
2y 5m to grant Granted Jan 06, 2026
Patent 12490754
WHEY PROTEIN-BASED, HIGH PROTEIN, YOGHURT-LIKE PRODUCT, INGREDIENT SUITABLE FOR ITS PRODUCTION, AND METHOD OF PRODUCTION
2y 5m to grant Granted Dec 09, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

9-10
Expected OA Rounds
36%
Grant Probability
70%
With Interview (+33.7%)
3y 11m
Median Time to Grant
High
PTA Risk
Based on 558 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month